Efficacy and safety of the switch of Triumeq^® to generic (abacavir + lamivudine) + Tivicay^®: data at 48 weeks

Abstract

Introduction: Generic drugs are helpful to enhance the efficiency of the sanitary system. A generic coformulation of abacavir (ABC) and lamivudine (3TC) is available since 2016 in Spain. A report of our experience with its use is exposed.

Methods: Patients between February 2017 and June 2017 who were taking Triumeq^® were switched to the generic ABC + 3TC plus DTG. Efficacy, safety, reasons for discontinuation and costs savings were evaluated at 48 weeks.

Results: Switch was made in 93 patients, with a median age of 47 years and a mean time of 12.33 years with HIV infection. Six patients (6.5%) discontinued the new ART, being toxicity of the central nervous system the most frequent reason. The effective saving derived from the change after 1 year of treatment was 151.127 €.

Conclusions: The change from Triumeq^® to a generic regimen of ABC + 3TC and another pill of DTG seems to be safe and efficient at 48 weeks.

Keywords:

• Dolutegravir
• drugs
• generic
• drugs
• switch
• HIV
• antiretroviral treatment

Disclosure statement

No potential conflict of interest was reported by the authors.